{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:53:21Z","timestamp":1761490401290,"version":"3.40.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.beha.2017.10.004","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T08:01:15Z","timestamp":1509523275000},"page":"23-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of untreated advanced stage follicular lymphoma: Role of patient discernment"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8746-4240","authenticated-orcid":false,"given":"Jayadev Manikkam","family":"Umakanthan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew A.","family":"Lunning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.beha.2017.10.004_bib1","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","article-title":"Follicular lymphoma: evolving therapeutic strategies","volume":"127","author":"Kahl","year":"2016","journal-title":"Blood"},{"issue":"9873","key":"10.1016\/j.beha.2017.10.004_bib2","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.beha.2017.10.004_bib3","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2017.10.004_bib4","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2017.10.004_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/0003-4819-90-1-10","article-title":"No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types","volume":"90","author":"Portlock","year":"1979","journal-title":"Ann Intern Med"},{"issue":"23","key":"10.1016\/j.beha.2017.10.004_bib6","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin's lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N\u00a0Engl J Med"},{"issue":"2 Suppl 2","key":"10.1016\/j.beha.2017.10.004_bib7","first-page":"11","article-title":"The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment","volume":"25","author":"Young","year":"1988","journal-title":"Semin Hematol"},{"issue":"9383","key":"10.1016\/j.beha.2017.10.004_bib8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beha.2017.10.004_bib9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"lancet Oncol"},{"issue":"29","key":"10.1016\/j.beha.2017.10.004_bib10","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"10.1016\/j.beha.2017.10.004_bib11","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or Re-Treatment trial for low\u2013tumor burden follicular lymphoma: eastern cooperative oncology group protocol E4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.beha.2017.10.004_bib12","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.29372","article-title":"Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: a cost-effectiveness analysis","volume":"121","author":"Prica","year":"2015","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.beha.2017.10.004_bib13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jama.1988.03410070057028","article-title":"Chronic fatigue in primary care: prevalence, patient characteristics, and outcome","volume":"260","author":"Kroenke","year":"1988","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.beha.2017.10.004_bib14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/BF02598083","article-title":"Fatigue in primary care","volume":"7","author":"Cath\u00e9bras","year":"1992","journal-title":"J\u00a0General Intern Med"},{"issue":"31","key":"10.1016\/j.beha.2017.10.004_bib15","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","article-title":"Watchful waiting in low\u2013tumor burden follicular lymphoma in the rituximab era: results of an F2-study database","volume":"30","author":"Solal-C\u00e9ligny","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.beha.2017.10.004_bib16","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2017.10.004_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00277-002-0581-1","article-title":"Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab","volume":"82","author":"Herold","year":"2003","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.beha.2017.10.004_bib18","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"year":"2017","series-title":"Bendamustine plus rituximab (BR) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study","author":"Rummel","key":"10.1016\/j.beha.2017.10.004_bib19"},{"issue":"S2","key":"10.1016\/j.beha.2017.10.004_bib20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/hon.2437_130","article-title":"First-line treatment of INHL or MCL patients with BR or R-CHOP\/R-CVP: RESULTS of the BRIGHT 5-year follow-up study","volume":"35","author":"Flinn","year":"2017","journal-title":"Hematol Oncol"},{"year":"2016","series-title":"Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomized phase 3 GALLIUM study","author":"Marcus","key":"10.1016\/j.beha.2017.10.004_bib21"},{"issue":"9759","key":"10.1016\/j.beha.2017.10.004_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"year":"2014","series-title":"End of rituximab maintenance for low\u2013tumor burden follicular lymphoma","author":"Friedberg","key":"10.1016\/j.beha.2017.10.004_bib23"},{"issue":"23","key":"10.1016\/j.beha.2017.10.004_bib24","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2017.10.004_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","article-title":"Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times","volume":"156","author":"Wahlin","year":"2012","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2017.10.004_bib26","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A\u00a0clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's lymphoma classification project","volume":"89","year":"1997","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2017.10.004_bib27","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdw185","article-title":"Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL","volume":"27","author":"Koch","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.beha.2017.10.004_bib28","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.beha.2017.10.004_bib29","first-page":"186","article-title":"Successful treatment of non-Hodgkin\u2019s lymphoma with rituximab and dose-adjusted CHOP therapy in a patient with concomitant end-stage renal disease requiring haemodialysis","volume":"4","author":"Kawano","year":"2011","journal-title":"Nephrol Dial Transplant Plus"},{"key":"10.1016\/j.beha.2017.10.004_bib30","article-title":"Pharmacokinetics and toxicity profile of bendamustine in myeloma patients with end-stage renal disease","volume":"3","author":"Preiss","year":"2003","journal-title":"Group"},{"issue":"6","key":"10.1016\/j.beha.2017.10.004_bib31","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3109\/10428194.2013.836600","article-title":"The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis","volume":"55","author":"Nordstrom","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2017.10.004_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40268-012-0001-5","article-title":"Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy","volume":"13","author":"Dubbelman","year":"2013","journal-title":"Drugs R"},{"issue":"3","key":"10.1016\/j.beha.2017.10.004_bib33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.10213","article-title":"Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis","volume":"71","author":"Jillella","year":"2002","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.beha.2017.10.004_bib34","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/annonc\/mdp598","article-title":"Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients","volume":"21","author":"Janus","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.beha.2017.10.004_bib35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000350746","article-title":"Treatment of a frail older patient with diffuse large B-cell lymphoma on maintenance dialysis: attenuated immunochemotherapy and adapted care plan","volume":"6","author":"de Barros Pontes","year":"2013","journal-title":"Case Rep Oncol"},{"issue":"8","key":"10.1016\/j.beha.2017.10.004_bib36","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nrneph.2009.97","article-title":"Chemotherapy-associated renal dysfunction","volume":"5","author":"Sahni","year":"2009","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.beha.2017.10.004_bib37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.7326\/0003-4819-88-2-168","article-title":"Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization","volume":"88","author":"Bristow","year":"1978","journal-title":"Ann Intern Med"},{"issue":"24","key":"10.1016\/j.beha.2017.10.004_bib38","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1161\/hc4901.102568","volume":"104","author":"Hunt","year":"2001","journal-title":"Circulation"},{"issue":"28","key":"10.1016\/j.beha.2017.10.004_bib39","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2017.10.004_bib40","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:01:15Z","timestamp":1603234875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692617300555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1521692617300555"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2017.10.004","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of untreated advanced stage follicular lymphoma: Role of patient discernment","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2017.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}